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It has recently been shown that substance P (SP) plays a major role in the secondary 
injury process following traumatic brain injury (TBI), particularly with respect to neuroin-
flammation, increased blood–brain barrier (BBB) permeability, and edema formation. 
Edema formation is associated with the development of increased intracranial pressure 
(ICP) that has been widely associated with increased mortality and morbidity after neu-
rotrauma. However, a pharmacological intervention to specifically reduce ICP is yet to be 
developed, with current interventions limited to osmotic therapy rather than addressing 
the cause of increased ICP. Given that previous publications have shown that SP, NK1 
receptor antagonists reduce edema after TBI, more recent studies have examined
whether these compounds might also reduce ICP and improve brain oxygenation after 
TBI. We discuss the results of these studies, which demonstrate that NK1 antagonists 
reduce posttraumatic ICP to near normal levels within 4 h of drug administration, as 
well as restoring brain oxygenation to near normal levels in the same time frame. The 
improvements in these parameters occurred in association with an improvement in BBB 
integrity to serum proteins, suggesting that SP-mediated increases in vascular permea-
bility significantly contribute to the development of increased ICP after acute brain injury. 
NK1 antagonists may therefore provide a novel, mechanistically targeted approach to 
the management of increased ICP.
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Traumatic brain injury (TBI) has been identified as one of the leading causes of death and disability 
in individuals less than 40 years of age in developed countries (1, 2). Despite the significance of this 
public health issue, there is currently no accepted therapy that can improve outcome (3), largely 
because the pathophysiological factors and their mechanistic interaction in the injury process have 
not been well characterized. In addition to the primary (mechanical) injury caused at the time of 
the traumatic event, secondary injury factors play a major role in resultant neuronal cell death that 
results in lifelong disability experienced by many survivors. While a number of secondary injury 
factors have been identified (4, 5), water accumulation, or brain edema, has been recognized as being 
closely associated with patient outcome (6). Indeed, up to half of all deaths following TBI having been 
attributed to brain edema (7, 8). A number of treatment strategies have been introduced to relieve 
edema-associated brain swelling (9); however, these target the end result of the edematous process 
[increased intracranial pressure (ICP)] rather than the cause. These strategies include administra-
tion of hyperosmotic agents and barbiturates, hypothermia, hyperventilation, cerebrospinal fluid 
(CSF) drainage, and decompressive craniotomy (10). However, significant improvements in patient 
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mortality and morbidity have not been observed with these 
interventions, largely because they do not attenuate the specific 
mechanisms associated with edema formation after TBI.
Increased ICP can locally compress tissue, reduce cerebral 
perfusion, reduce brain oxygenation with resultant hypoxia 
and ischemia, result in brain herniation and, in severe cases, 
cause death. For ICP to increase after TBI, the volume within 
the confines of the skull must increase either through vasodila-
tion, hemorrhage, increased CSF production, reduced CSF 
reabsorption, or edema. If ICP is increased because of edema, it 
follows that the total fluid volume of the cranial vault must have 
increased, and the only source of this water can be the vascu-
lature (11, 12). Water movement from the cerebral vasculature 
to the brain parenchyma is known as vasogenic edema and has 
been well described as a significant component of early edema 
formation after TBI (6). Moreover, vasogenic edema is known to 
be permissive for subsequent cytotoxic edema (13), which then 
initiates a feedback loop that further drives increases in vasogenic 
edema and consequently ICP (12). Vasogenic edema requires 
that there is increased blood–brain barrier (BBB) permeability 
to serum proteins. A net movement of water from the vascular 
compartment then follows extravasation of blood plasma pro-
teins into the brain parenchyma, leading to a disruption of fluid 
homeostasis. Given the increase in the volume of the brain tissue 
under these circumstances, ICP rises and negatively influences 
patient outcomes (14). In addition, the loss of barrier integrity 
following acute injury to the brain allows peripheral immune cells 
to cross the barrier and further contribute to and exacerbate the 
inflammatory processes within the brain (15).
Increased BBB permeability after TBI with subsequent edema 
formation has been recently linked to substance P (SP) release 
(16, 17). Moreover, the increased BBB permeability and edema 
formation after acute brain injury, together with the associated 
increased ICP, was reduced by administration of a SP, NK1 recep-
tor antagonist (17–19). Accordingly, the current review focuses 
on the role of SP in TBI, particularly in relation to edema forma-
tion and increased ICP.
SUBSTANCe P
Substance P is peptide of 11 amino acids and belongs to the 
large tachykinin peptide family containing over 40 tachykinins, 
including neurokinin A, neurokinin B, neuropeptide-γ (NPγ), 
and the recently identified hemokinin 1. Originally identified 
in the 1930s by von Euler and Gaddum for its potent smooth 
muscle and hypotensive properties (20), SP is now known as a 
neurotransmitter that is released from primary afferent neurons 
in both the peripheral and central nervous system, as well as from 
non-neuronal cells such as inflammatory and endothelial cells 
(21, 22). In the nervous system, SP is localized to nuclei such as 
the substantia nigra and the medial amygdaloid nucleus, as well 
as to capsaicin-sensitive sensory neurons (23) where it is released 
in response to stimulation of the transient receptor potential 
channels by mechanical stimulation, temperature, pH changes, 
and ligand binding (24). Following release, SP can bind to tachy-
kinin NK receptors to exert direct postsynaptic actions as a neu-
rotransmitter or modulate other non-neuronal targets (22). The 
NK receptors are 7-transmembrane domain, G-protein-coupled 
receptors, with three, known as the NK1, NK2, and NK3 recep-
tor, having been identified to date (21). Each of the tachykinin 
neuropeptides is able to bind all three receptor types depending 
on receptor availability and concentration of the neuropeptide, 
indicating that there is a degree of cross-reactivity among the 
receptors (21). SP normally has the highest affinity for the NK1 
receptor, which given the predominance of the NK1 receptor in 
the adult brain (25) makes SP the tachykinin of particular interest 
in the context of CNS injury.
Synthesis
Two genes exist that are relevant to tachykinin synthesis, namely 
the preprotachykinin (PPT) A gene and the PPTB gene. Four dif-
ferent forms of mRNA are expressed through alternative splicing 
from the PPTA gene (26), the α and δ forms exclusively encoding 
for the synthesis of SP, while the β and γ forms encode synthesis 
of SP, as well as NKA, neuropeptide K (NPK), and NPγ; NPK and 
NPγ are elongated forms of NKA. In the brain, αPPTA expres-
sion is predominant, while in the peripheral tissues, βPPTA 
and γPPTA mRNAs are abundant (27). The PPTB gene encodes 
neurokinin B (22).
Similar to all neuropeptides, SP is synthesized on ribosomes 
that are exclusively present in the cell body. The mRNA encoding 
the tachykinin is initially translated into a larger protein precur-
sor from which SP is subsequently released by the actions of 
proteases called convertases. Cleavage points for the convertases 
are doublets of cationic residues (26). After release, the actions of 
tachykinins are terminated by diffusion away from the receptor 
site or degradation by extracellular peptidases, the slow nature of 
these processes accounting for their prolonged effects (28).
Metabolism
Several enzymes are associated with SP metabolism including 
neutral endopeptidase (NEP) (29), angiotensin-converting 
enzyme (ACE) (30), SP-degrading enzyme (31), post-proline 
endopeptidase (32), dipeptidyl aminopeptide IV (33), cathepsin-
D (34), and cathepsin-E (35). The individual cellular localization 
of NEP and/or ACE suggests that these enzymes are most likely 
responsible for the in vivo cleavage of SP (36), albeit that all of 
these enzymes have been shown to cleave the tachykinin in vitro. 
Hydrolysis of SP by both ACE and NEP removes the carboxyl 
terminal required for binding to the tachykinin receptors (30). 
NEP hydrolyzes SP in the peripheral tissues, brain, and spinal 
cord (37–39) with ACE-degrading SP in the plasma, CSF, and the 
substantia nigra (40), as well as contributing to the degradation 
of peptide fragments released by NEP.
Localization
Immunohistochemistry has shown that SP is present in the dien-
cephalon, telencephalon, rhinencephalon, hippocampus, basal 
ganglia, pons, amygdala, hypothalamus, septal areas, myelen-
cephalon mesencephalon, metencephalon, and spinal cord (41). 
SP immunopositive nerve fibers are common in most autonomic 
ganglia (42–44) and are detected in trigeminal and dorsal root 
ganglia (45, 46) as well as in intrinsic neurons of the gut (47). It is 
thought to play a modulatory role in the autonomic ganglia, the 
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best characterized response being observed in guinea pig inferior 
mesenteric ganglion where SP mimics a slow depolarization 
that can be evoked by repetitive afferent nerve stimulation (48). 
Peripheral inflammation has been shown to increase SP immu-
noreactivity in the superficial layers of the spinal cord (49) and 
increase release of SP (50). Damage to neurons or their intense 
activation also induces neuropeptide gene expression leading to 
alterations in neuropeptide biosynthesis (51). Specifically, during 
noxious stimulation or neurogenic inflammation in the periph-
ery, there is an upregulation (28) of PPT mRNA expression (52) 
and NK1 receptor mRNA (53).
NeUROGeNiC iNFLAMMATiON
Sensory nerve fibers positive for both SP and calcitonin gene-
related peptide (CGRP) are found surrounding most blood 
vessels throughout the body. In particular, cerebral arteries have 
a rich supply of sensory neurons, suggesting that they have a role 
as mediators of the inflammatory process following injury. The 
release of these neuropeptides, including SP, is neurally elicited 
and results in a painful local inflammatory response known as 
neurogenic inflammation, characterized by increased vascular 
permeability, protein extravasation, mast cell degranulation, 
and vasodilation (54). These changes in vascular permeability 
and in blood vessel diameter result in localized swelling of the 
tissue (54). Also occurring are tissue-specific responses to neu-
ropeptide stimulation including constriction of the bronchioles 
in the airways and contraction and/or relaxation of the smooth 
muscle in the bladder. SP is also widely considered to be the most 
active mediator of neurogenic inflammation, even though it is 
well known that other neuropeptides such as CGRP are involved. 
Nonetheless, CGRP potentiates the effects of SP by enhancing the 
bioavailability of SP through competition with SP for metabolism 
by endopeptidases and by increasing the expression of the NK1 
tachykinin receptor (55). Neurogenic inflammation in itself 
also leads to an increase in the PPTA and NK1 receptor mRNA 
transcript (28), which encodes SP and its primary receptor, 
respectively.
A role for classical inflammation in the pathophysiology of 
secondary injury following TBI is well known (15); however, brain 
neurogenic inflammation has remained relatively unexplored 
until recently. First characterized in peripheral tissue, neurogenic 
inflammation has now been well described in a number of studies 
following acute brain injury (3, 16, 56). Its occurrence in the CNS 
was first demonstrated when electrical or chemical stimulation of 
the Dura mater, or acute capsaicin administration (a TRPV1 ago-
nist), produced a local neurogenic inflammatory response in the 
form of increased protein extravasation that was not observed in 
the brain parenchyma itself or in the Pia mater (57). Subsequently 
in stroke, activation of endothelial NK1 receptors on blood vessels 
was shown to contribute to cerebral edema (58). Administration 
of SP was then shown in rats to produce a profound increase 
in plasma protein extravasation in the Dura mater, which was 
blocked when an NK1 receptor antagonist was administered and 
exacerbated by administration of either NEP or ACE inhibitors 
(59). In studies of TBI, inhibition of posttraumatic neurogenic 
inflammation by prior depletion of sensory neuropeptides using 
chronic capsaicin pretreatment attenuated increased BBB perme-
ability, and the development of edema and functional deficits 
(60, 61), with subsequent studies demonstrating that ACE inhibitors 
exacerbated histological damage and functional deficits after TBI 
(62). Further studies in stroke established that reversible ischemic 
stroke resulted in increased brain perivascular immunoreactivity 
to SP with associated edema formation (63), while decreased SP 
immunoreactivity in association with increased NK1 immuno-
reactivity in both rat and human spinal cord injury suggested 
a role for neurogenic inflammation in this form of CNS injury 
(64, 65). Finally, activation of the multimodal TRPV1 receptor 
that is linked to SP release initiates neurogenic inflammation and 
is associated with increased BBB permeability, an effect abolished 
by the TRPV1 antagonist capsazepine and by an NK1 antagonist 
(66). Collectively, these data provide strong support that neuro-
genic inflammation involving the release of SP can occur within 
the setting of acute CNS injury.
SP iN TBi
Our own studies have shown that SP release is a ubiquitous fea-
ture of TBI and is associated with marked increases in BBB per-
meability, edema formation, and the development of functional 
deficits (56). Specifically, an increase in cerebral perivascular SP 
is observed following TBI as early as 5 h after TBI and persisting 
for at least 24 h following trauma (17). In human postmortem 
TBI tissue, the increased SP immunoreactivity colocalized with 
APP in perivascular nerve fibers suggesting that injury to these 
perivascular neurons was associated with SP release (67). The 
authors also reported that increased SP was apparent in corti-
cal neurons and astrocytes, similar to observations made in the 
rodent models (17). SP mRNA levels as determined by PCR 
analysis remained elevated until at least 3 days posttrauma (68), 
suggesting persistent synthesis and release over this time frame. 
Moreover, serum levels of SP were elevated after TBI, with sig-
nificant increases observed in both experimental (17) and human 
TBI, the latter having been associated with increased severity 
and mortality in patients (69). As discussed earlier, when SP 
catabolism is inhibited by the administration of an ACE inhibitor, 
further increases in SP immunoreactivity is observed together 
with an exacerbation of injury and neurological dysfunction (62).
Such increases in SP levels following trauma have been associ-
ated with increased permeability of the BBB and the formation 
of cerebral edema (12). Specifically, increased perivascular SP 
immunoreactivity after TBI colocalized with increased extrava-
sation of Evan’s blue dye, a marker of increased BBB perme-
ability (17). The authors proposed that where SP was bound to 
a vascular endothelial cell, BBB permeability to vascular protein 
was increased. This increased BBB permeability to proteins was 
associated with the development of cerebral vasogenic edema, 
together with the development of persistent motor and cognitive 
deficits (17).
Further evidence supporting a role for SP in neurogenic 
inflammation after TBI has been obtained using NK1 antago-
nists (3). For example, the NK1 tachykinin receptor antagonist 
N-acetyl-l-tryptophan (NAT) attenuated increased BBB perme-
ability, cerebral edema, and functional deficits when administered 
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at 30 min after TBI (17). Attenuation of BBB permeability toward 
Evan’s blue was dose dependent and used to determine the optimal 
dose. The therapeutic window of the antagonist was established as 
12 h with rats administered with the compound at such delayed 
time points still demonstrating reductions in neuronal injury and 
an improvement in functional outcome (70). However, only a 
membrane permeable form of the drug was effective at these later 
time points, suggesting that the efficacy at delayed time points was 
dependent on central penetration of the compound. These studies 
also established that inactive enantiomers of the active ligands 
were ineffective irrespective of the time point, emphasizing that 
neuroprotective efficacy was dependent on actual binding to the 
NK1 receptor and the inhibition of its activity.
Most experimental studies are confined to male animals, 
largely to avoid the confounding effects of gender related hor-
mones. However, the efficacy of the NK1 antagonists in TBI 
has also been demonstrated in female animals (71). Specifically, 
increased SP immunoreactivity was again apparent after diffuse 
TBI and the NK1 antagonist, NAT, reduced BBB permeability 
to albumin, reduced axonal injury, and significantly improved 
functional outcome. Moreover, it reduced edema formation at 
24  h after TBI by more than 80%. In related studies involving 
reversible ischemic stroke, administration of the NK1 antagonist 
at 4  h after stroke onset resulted in reduced BBB permeability 
and edema formation at 24 h, plus improved functional outcome 
over 1  week (18). Indeed, treatment with the NK1 antagonist 
was more effective than neuropeptide depletion with capsaicin 
pretreatment (72) and importantly did not reduce the effective-
ness of tissue plasminogen activator (tPA) treatment (73). When 
combined with tPA, the NK1 antagonist actually appeared to 
stabilize the BBB and extend the therapeutic window of the tPA 
treatment, which in clinical scenarios has been limited to 4 h.
iCP AND BRAiN OXYGeNATiON  
AFTeR TBi
Various animal models have been developed to reproduce 
aspects of the pathophysiology observed clinically after TBI, 
with rat models being the most widely used in experimental 
neurotrauma because they are considered cost effective and 
have readily available outcome measures (74). Disappointingly, 
however, treatments that have proven to be neuroprotective 
in these rodent models have not successfully translated to the 
clinical environment, thus emphasizing the importance of vali-
dating promising therapeutic agents in arguably more clinically 
relevant large animal models before progressing to clinical trials. 
Accordingly, we have developed a large animal model of diffuse 
TBI using sheep that reproduces consistent changes in ICP and 
brain tissue oxygenation (PbtO2) that are more representative of 
the clinical situation (75, 76). The use of a large animal, ovine 
model of TBI delivers a number of advantages that are not pre-
sent in the more commonly used rodent models of TBI. First, 
there is the presence of a gyrencephalic brain with large white 
matter domains as opposed to a lissencephalic brain. The pres-
ence of gyri alters the mechanical response of the brain to TBI, 
while the large white matter domains alter the edema response. 
Sheep also have a significant tentorium cerebelli thus separating 
the brain into supratentorial and infratentorial compartments, 
similar to that observed in humans (77). These differences in 
cerebral folding, gray matter/white matter distribution, and 
brain compartmentalization may therefore contribute to the 
inability of some groups to consistently produce posttraumatic 
ICP responses in rats in the absence of mass lesions or hypoxia 
(78). Moreover, unlike rodents, sheep have remarkably similar 
ICP and PbtO2 values to humans, with normal ICP in the sheep 
between 6 and 9 mm Hg and PbtO2 being above 40 mm Hg, as well 
as the similar responses in these important physiological vari-
ables after TBI (75). Finally, large animals are amenable to using 
the same neurosurgical techniques and surgical instrumentation 
as that used clinically, which is also an advantage.
We have previously shown that ICP in moderate/severely 
injured sheep increases from control values of approximately 
7  mm Hg to above 20  mm Hg within 1  h of the injury [(75); 
Figure 1A] and remains at those elevated levels in the hours that 
follow. This increase in ICP is consistent with the presence of 
vasogenic edema formation previously reported in diffuse TBI, 
and peaking between 4 and 6 h after injury (79, 80). Indeed, in 
the sheep brain, there was significant albumin extravasation at 
these early time points after TBI, confirming the presence of a 
more permeable BBB (80). When the NK1 antagonist, NAT, was 
administered at 30  min postinjury, there was a significant and 
sustained decline in ICP (19). Focusing on the time course of 
those previously reported changes [(19); Figure  1A], the NK1 
receptor antagonist significantly reduced ICP by 32% within 
3.5 h of administration, whereas ICP continued to increase by a 
further 36% in vehicle-treated animals. By 4 h after injury, ICP 
in the NK1-treated animals was half of vehicle-treated animals 
(p < 0.001) and approaching normal values (19).
The reoxygenation of brain tissue after TBI is an important 
part of effective therapeutic intervention, with restoration of 
aerobic energy metabolism essential to enable damaged tissue to 
recover. In the ovine model of diffuse TBI, injury typically results 
in a significant fall in PbtO2 to less than 50% of normal values, a 
reduction that persisted over the next few hours [(75); Figure 1B]. 
Administration of an NK1 receptor antagonist increased PbtO2 to 
more than 80% of control values by 4 h after TBI (81), consistent 
with the close relationship that has been previously described 
between ICP and PbtO2 after TBI (75). This improved oxygena-
tion of the brain following administration of the NK1 antagonist 
may, in part, account for the improved neuronal cell survival 
and associated improvement on functional outcome previously 
reported (3).
A number of other experimental compounds have been suc-
cessfully used to reduce edema formation in experimental TBI 
studies, including more recently progesterone and magnesium 
(4, 82), both of which have been unsuccessful in clinical trials to 
date (83, 84). Notably, when tested in our sheep model of TBI, our 
preliminary results also showed that both compounds had little 
effect on ICP or PbtO2 after TBI (unpublished results). The hyper-
osmotic compound mannitol is used clinically in the management 
of increased ICP following TBI, although considerable variability 
has been observed in both the ICP (9, 85) and PbtO2 response (86) 
in these clinical studies. The mechanism of action of mannitol 
is to draw water out of brain tissue into the vasculature where 
FiGURe 1 | Time course of changes in (A) intracranial pressure (ICP) and  
(B) PbtO2 following moderate to severe diffuse traumatic brain injury in sheep 
and treatment with an NK1 antagonist [adapted from Ref. (19, 75)]. Briefly, 
2-year-old isoflurane anesthetized merino sheep were injured using the  
humane stunner and monitored for ICP and PbtO2. N-acetyl-l-tryptophan  
(NAT: 2.5 mg/kg i.v.) was administered at 30 min after injury. ⚬ = sham 
(uninjured) animals (n = 9); ⦁ = vehicle (saline) treated animals (n = 9); 
▪ = NAT-treated animals (n = 10). *p < 0.05; **p < 0.01; ***p < 0.001 versus 
vehicle-treated animals (two-way ANOVA followed by Bonferroni post hoc tests).
FiGURe 2 | Schematic illustrating the process of transcytosis where vascular 
proteins such as albumin are transported across the endothelial cells of the 
blood–brain barrier via caveolae. The creation of a protein osmotic gradient 
then drives water influx from the vasculature to the brain via aquaporin 
channels. NK1 receptors are present in caveolae.
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its presence has increased the osmotic pressure. This does not 
attenuate the potential mechanisms driving an increase in ICP, 
where the BBB after TBI is more permeable to proteins. There is 
also the potential that mannitol may actually cross into the brain 
parenchyma through the more permeable BBB, increasing the 
brain osmotic pressure and causing water influx with a rebound 
increase in ICP (87). By contrast, the mechanism of action of 
the NK1 receptor antagonist involves reducing BBB permeability 
and inhibiting the development of vasogenic edema (17), thus 
eliminating any possibility for a rebound increases in ICP.
MeCHANiSM OF ACTiON
Vasogenic edema occurs when a BBB with increased perme-
ability to vascular protein facilitates the influx of proteins such 
as albumin into the brain; vascular water subsequently follows 
down the osmotic gradient that has been created. A number of 
events have been associated with both the early and late BBB 
disruption described after TBI, including classical inflammation, 
activation of matrix metalloproteinases, metabolic imbalances, 
and breakdown of tight junction proteins (88–90). However, the 
increased movement of proteins across the BBB does not require 
the physical breakdown of the barrier or the tight junctions, but 
rather can occur via caveolae in a process known as transcytosis 
(91). Indeed, in the hours following TBI, the tight junctions of 
the BBB have been shown to be intact (92, 93) as opposed to the 
caveolae that are upregulated (93). Increased caveolin-1 expres-
sion, a major constituent of caveolae, is thus thought to reflect an 
increase in albumin transcytosis after TBI (93), and account for 
the vasogenic edema that ensues (Figure 2). NK1 receptors have 
been shown to be located in caveolae (94–96), suggesting that 
their activation may play a role in regulating transcytosis. The 
fact that NK1 antagonists reduce BBB permeability after TBI, at 
a time when the tight junctions are intact and the BBB is more 
permeable to albumin, supports this suggestion. Thus, the release 
of perivascular SP after TBI activates NK1 receptors, including 
those localized to caveolae. This activates transcytotic albumin 
transport from the vasculature to the brain parenchyma, creating 
a protein osmotic gradient that drives water entry through aqua-
porin channels with subsequent edema formation. By inhibiting 
transcytosis, the NK1 antagonists attenuate the development 
of an osmotic gradient and negate the requirement for water 
movement from the vasculature to the brain. Without increased 
volume from vascular-derived water, there will not be an edema-
associated increase in ICP, and any water that has accumulated in 
the brain will now be able to efflux via aquaporin channels (97).
CONCLUSiON
NK1 antagonists reduce posttraumatic ICP to near normal levels 
within a few hours of drug administration. They also restore 
PbtO2 to normal levels in the same time frame, confirming an 
association between ICP and PbtO2 after TBI. The effects of 
NK1 antagonists on these parameters are more consistent and 
generally superior to mannitol, without the risk of rebound 
increases in ICP, and significantly better than the experimental 
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treatment strategies progesterone and magnesium, which are 
ineffective. We posit that SP-mediated increases in protein 
transcytosis increases vascular permeability, significantly con-
tributing to the development of increased ICP after acute brain 
injury. Administration of NK1 antagonists reduces this protein 
transcytosis, eliminating the driver for vasogenic edema and 
thus reducing increased ICP. Accordingly, the NK1 antagonists 
warrant further investigation as a novel therapeutic approach to 
the management of increased ICP.
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